The results of a recent study has shown that heart-failure patients who are given AstraZeneca’s Crestor and standard drugs are just as likely to have heart attacks and strokes or die of cardiovascular problems as those on standard therapy alone.
AstraZeneca has hoped to establish Crestor as the first cholesterol-lowering statin to show clear benefits in treating elderly patients with the chronic heart condition.
Results of a 5,000-patient study showed Crestor was no better than a placebo, although it did cut levels of “bad” LDL cholesterol and C-reactive protein and reduced hospitalizations for cardiovascular causes. AstraZeneca said that the study had been “novel and challenging” and, though unsuccessful, had established Crestor’s safety in heart-failure patients.
(Source)
